Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | IDE | P14735 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.30 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473514 | 0.80 | ALDH1A1 (0.38) | ALDH1A1CNR2IDEKMT2AGAA | |
| SCHEMBL4405716 | 0.78 | ALDH1A1 (0.42) | ALDH1A1CNR2CYP1A2TDP1LMNA | |
| SCHEMBL4413524 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CNR2CYP1A2TDP1SMN1; SMN2 | |
| SCHEMBL4408301 | 0.76 | CNR2 (0.32) | ALDH1A1CNR2CYP1A2TDP1 | |
| SCHEMBL4407893 | 0.76 | CNR2 (0.32) | ALDH1A1CNR2CYP1A2TDP1 | |
| SCHEMBL25006629 | 0.76 | CYP1A2 (0.35) | ALDH1A1CNR2CYP1A2TDP1 | |
| SCHEMBL4409241 | 0.76 | CNR2 (0.32) | ALDH1A1CNR2CYP1A2TDP1LMNA | |
| SCHEMBL6096759 | 0.75 | SLC1A3 (0.39) | — | |
| SCHEMBL16522416 | 0.75 | ALDH1A1 (0.34) | ALDH1A1IDEKMT2AGAAMEN1 | |
| SCHEMBL3080043 | 0.75 | GRIA4 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032229-A1 | PYRIDINE RING-SUBSTITUTED PYRIDAZINOL COMPOUNDS AND DERIVATIVES, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND APPLICATIONS THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2021-02-04 | — | — | US | disclosed |
| WO-2017093543-A2 | ANTI-BACTERIAL COMPOUNDS | AUSPHERIX LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| EP-1859782-B1 | Composition for coloring and/or lightening human hair comprising tetrazoles | HENKEL AG & CO KGAA (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-7618987-B2 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK & CO., INC. (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1859782-A1 | Composition for coloring and/or lightening human hair comprising tetrazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-7276520-B2 | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070191433-A1 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK SHARP & DOHME CORP. | 2007-08-16 | — | — | US | disclosed |
| US-20070060584-A1 | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers | MERCK & CO., INC. | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032229-A1 | PYRIDINE RING-SUBSTITUTED PYRIDAZINOL COMPOUNDS AND DERIVATIVES, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND APPLICATIONS THEREOF | CBR3, CBR1, H1-0 | ALDH1A1 1438/4885CNR2 99/4885CYP1A2 18/4885 |
| US-20070060584-A1 | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers | TRPV1, TRPA1, TRPV3 | ALDH1A1 937/4885CNR2 173/4885CYP1A2 2278/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | ALDH1A1 534/4885CNR2 104/4885CYP1A2 443/4885 |
| US-20070191433-A1 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MC4R, MC5R, MC3R | ALDH1A1 2675/4885CNR2 260/4885CYP1A2 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.